Testing CKD-215 and D215 for BRCA-mutated ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 1 trial tests two experimental drugs (CKD-215 and D215) in adults with advanced ovarian, fallopian tube, or peritoneal cancer that has a BRCA gene mutation. The goal is to find safe and effective doses of these drugs for treating this type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19–75 years old
- You must have advanced high-grade ovarian, fallopian tube, or primary peritoneal cancer with a BRCA mutation
- Your body mass index (BMI, a measure of weight relative to height) must be between 18.0 and 28.0
- You cannot have stomach or digestive problems (like Crohn's disease or ulcers) that would prevent your body from absorbing the study drug
- You cannot have cancer that has spread to your brain, unless it is stable after treatment
- You cannot have had severe side effects (Grade 3 or higher) from D215, such as low blood counts, anemia, or taste changes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This study tests two new experimental drugs (XmAb541 and XmAb808) designed to fight advanced ovarian cancer by activating your immune system. You'll be closely monitored to see how safe the drugs are and how your body tolerates them.
This early-phase study tests whether KM1 is safe and can shrink or control ovarian, fallopian tube, or primary peritoneal cancer that has come back or not responded to standard treatment. It may help people who have limited options, but eligibility is strict to keep participants safe.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.